enhanc
infect
replic
porcin
reproduct
respiratori
syndrom
prr
viru
presenc
specif
antibodi
demonstr
vitro
vivo
phenomenon
known
antibodydepend
enhanc
ade
ade
consideredto
bea
signific
obstacl
todevelopingeffectivevaccinesformani
virusesforwhich
ade
report
sincevirusspecif
antibodi
matern
origin
confer
vaccin
facilit
entri
viru
target
cell
sometim
result
increas
sever
diseas
studi
role
specif
prr
viral
epitop
ade
andor
viru
neutral
vn
assess
vitro
use
monoclon
antibodi
mab
prr
viral
protein
nucleocapsid
n
matrix
glycoprotein
gp
mab
recongn
distinct
epitop
one
protein
oneway
ade
vn
assay
perform
vitro
use
homolog
prr
viru
isol
presenc
absenc
mab
ade
activ
determin
detect
signific
increas
progeni
viru
yield
porcin
alveolar
macrophag
cultur
presenc
individu
mab
neutral
activ
determin
detect
signific
reduct
complet
block
viru
replic
cell
presenc
ofindividu
mab
mab
could
categor
group
enhanc
neutral
neither
viral
epitop
capabl
induc
neutral
antibodi
appear
resid
protein
epitop
may
induc
ademedi
antibodi
associ
n
protein
identif
viral
protein
antigen
epitop
respons
adeand
vnmediat
antibodi
may
provid
basi
develop
efficaci
secondgener
vaccin
control
prr
viru
yet
epitop
map
remain
done
decad
porcin
reproduct
respiratori
syndrom
prr
diseas
great
signific
swine
industri
sinc
first
appear
catastroph
clinic
outbreak
swine
herd
north
america
europ
late
wensvoort
et
al
despit
effort
control
syndrom
diseas
still
respons
great
econom
loss
pig
produc
throughout
world
porcin
reproduct
respiratori
syndrom
caus
prr
viru
prrsv
small
envelop
rna
viru
belong
famili
arterivirida
equin
arter
viru
eav
lactat
dehydrogenaseelev
viru
ldv
mice
simian
hemorrhag
fever
viru
shfv
cavanagh
conzelmann
et
al
meulenberg
et
al
although
smaller
size
lack
surfac
project
characterist
coronavirus
arterivirus
classifi
order
nidoviral
famili
coronavirida
common
trait
genom
organ
replic
strategi
cavanagh
prrsv
polyadenyl
singlestrand
nonseg
positivesens
rna
genom
kb
size
conzelmann
et
al
meulenberg
et
al
genom
consist
open
read
frame
orf
express
product
nest
set
subgenom
cotermin
mrna
orf
encod
viral
rnadepend
rna
polymeras
orf
postul
encod
structur
protein
protein
consist
identifi
virion
andor
lysat
virusinfect
cell
kd
nucleocapsid
n
kd
matrix
kd
envelop
e
protein
encod
orf
respect
bautista
et
al
conzelmann
et
al
meulenberg
et
al
meulenberg
et
al
nelson
et
al
yoon
et
al
protein
encod
orf
design
gp
indic
glycoprotein
number
design
orf
deriv
van
nieuwstadt
et
al
postul
associ
viral
membran
prrsv
possess
four
characterist
may
contribut
difficulti
diagnosi
control
diseas
includ
product
effect
vaccin
yoon
tropism
macrophag
macrophagelineag
cell
remark
antigen
variat
among
prrsv
field
isol
enhanc
viru
infect
presenc
antibodi
known
antibodydepend
enhanc
ade
abil
establish
persist
infect
tropism
macrophag
signific
impedi
expos
anim
develop
effect
local
system
immun
van
reeth
adair
antigen
variabl
potenti
render
useless
preexist
antibodi
capabl
neutral
viru
permit
develop
new
strain
evad
immun
system
revert
virul
poland
et
al
vennema
et
al
ade
facilit
attach
intern
viru
host
cell
macrophag
monocyt
fc
receptormedi
endocytosi
use
antibodi
present
subneutr
level
canceltirado
yoon
persist
signific
epidemiolog
implic
relat
viru
perpetu
herd
transmiss
anim
zimmerman
et
al
ade
viru
infect
describ
variou
virus
belong
differ
famili
variou
taxa
host
canceltirado
yoon
kuran
et
al
among
human
immunodefici
viru
type
mascola
et
al
prohaszka
et
al
robinson
et
al
ebola
viru
takada
et
al
west
nile
viru
fagbami
et
al
influenza
viru
ochiai
et
al
dengu
viru
dv
halstead
et
al
felin
infecti
periton
viru
fipv
corapi
et
al
equin
infecti
anemia
viru
wang
et
al
aleutian
diseas
viru
mink
porter
et
al
foot
mouth
diseas
viru
mason
et
al
name
ade
play
role
enhanc
opportun
virus
infect
target
cell
exacerb
diseas
due
ade
also
well
document
dv
fipv
infect
klik
klik
et
al
sangkawibha
et
al
szabo
et
al
mechan
biolog
signific
ade
well
describ
recent
review
articl
canceltirado
yoon
ade
consid
one
major
impedi
develop
efficaci
vaccin
certain
virus
fipv
dv
mascola
et
al
moren
olsen
minim
risk
associ
ade
control
diseas
vaccin
effort
made
formul
vaccin
induc
balanc
immun
respons
identifi
viral
compon
associ
ade
neutral
viru
infect
mascola
et
al
moren
addit
numer
research
studi
mechan
ade
particularli
cellular
event
besid
simpl
increas
uptak
viru
coupl
antibodi
ochiai
et
al
prohaszka
et
al
follow
studi
conduct
character
role
prr
viral
protein
ade
viru
neutral
identifi
respons
epitop
recogn
monoclon
antibodi
work
toward
develop
subunit
vaccin
would
offer
protect
prrsv
studi
attempt
identifi
epitop
associ
neutral
andor
ade
infect
role
individu
prr
viral
epitop
ade
viru
neutral
determin
use
panel
murin
monoclon
antibodi
mab
specif
variou
prrsv
protein
prior
conduct
ade
vn
test
compat
fc
portion
murin
mab
fc
receptor
fcr
porcin
alveolar
macrophag
pam
test
rosett
format
assay
amount
prrsvspecif
antibodi
ascit
fluid
measur
indirect
fluoresc
antibodi
ifa
test
adjust
level
enhanc
neutral
activ
mab
assess
util
vitro
ade
assay
oneway
viru
neutral
vn
test
respect
differ
viru
progeni
product
treat
nontreat
group
calcul
statist
compar
two
prr
virus
design
isup
use
ade
vn
assay
isol
collect
diseas
pig
swine
oper
iowa
kentucki
respect
use
antigen
produc
panel
mab
use
studi
tabl
virus
share
epitop
studi
except
recogn
mab
virus
propag
cell
highli
permiss
clone
african
monkey
kidney
cell
line
yang
et
al
strain
consid
homolog
regard
epitop
except
mab
found
kim
et
al
titrat
aliquot
kept
frozen
minu
use
porcin
alveolar
macrophag
pam
cell
line
use
ade
assay
pam
collect
piglet
free
prrsv
lung
lavag
previous
describ
yoon
et
al
use
ade
assay
pam
cultur
prepar
quickli
thaw
frozen
cell
suspend
sigma
chemic
co
st
loui
mo
usa
supplement
fetal
bovin
serum
fb
hyclon
laboratori
logan
ut
usa
mgml
gentamicin
sigma
chemic
co
antibioticantimycot
mixtur
compos
mgml
streptomycin
iuml
penicillin
mgml
amphotericin
b
sigma
chemic
co
seed
multiwellpl
cell
use
h
incub
humid
co
incub
cell
use
viru
titrat
vn
assay
use
cell
cultur
dulbecco
modifi
eagl
medium
dmem
sigma
chemic
co
supplement
mm
lglutamin
gibcobrl
life
scienc
grand
island
ny
usa
fc
mgml
gentamicin
sigma
chemic
co
antibioticantimycot
mixtur
cell
use
assay
h
incub
humidifi
co
incub
total
mab
specif
prrsv
obtain
mous
ascit
use
studi
mab
specif
distinct
epitop
n
protein
protein
specif
antibodi
level
mab
prrsv
strain
use
product
mab
summar
tabl
product
protein
specif
characterist
mab
previous
describ
yang
et
al
mab
isotyp
determin
commerci
mous
mab
isotyp
kit
isostrip
mous
monoclon
antibodi
isotyp
kit
roch
diagnost
corpor
indianapoli
usa
level
prrsvspecif
antibodi
mab
determin
commerci
elisa
kit
herdcheck
prr
idexx
laboratori
westbrook
usa
indirect
fluoresc
antibodi
test
level
antibodi
mab
adjust
titer
approxim
accord
ifa
test
result
prepar
viral
antigen
monolay
infect
ml
tcid
viral
suspens
isup
strain
prrsv
incub
normal
cell
control
prepar
ident
manner
cell
cultur
medium
instead
viru
h
incub
cell
wash
twice
phosphat
buffer
salin
pb
ph
fix
aceton
aqueou
solut
seri
dilut
made
mab
pb
fifti
microlit
mab
dilut
ad
triplic
well
incub
min
humidifi
environ
unbound
mab
wash
well
note
presenc
antigenantibodi
reaction
visual
ad
ml
goat
antimurin
igg
conjug
fluorescein
isothiocyan
fitc
kirkegaard
perri
laboratori
inc
gaithesburg
md
usa
well
perform
immunofluoresc
microscopi
prrsvspecif
antibodi
titer
mab
express
reciproc
highest
dilut
specif
fluoresc
observ
well
commerci
elisa
kit
herdcheck
prr
idexx
laboratori
inc
use
determin
prrsvspecif
antibodi
mab
direct
manufactur
two
except
instead
use
antiporcin
conjug
provid
kit
goat
antimous
igg
label
peroxidas
kirkegaard
perri
laboratori
inc
substitut
presenc
absenc
specif
antibodi
given
dilut
determin
use
optic
densiti
od
rather
sampletoposit
sp
ratio
kit
design
adjust
detect
swine
igg
sera
sampl
od
valu
higher
upper
limit
confid
interv
mean
od
normal
mous
ascit
consid
posit
antibodi
prrsv
compat
murin
antibodi
fc
receptor
porcin
macrophag
determin
rosett
assay
util
sheep
red
blood
cell
srbc
coat
murin
antisrbc
polyclon
antibodi
murin
antisrbc
serum
obtain
balbc
mice
follow
seri
intraperiton
inocul
ml
suspens
freshli
collect
wash
srbc
interv
level
antisrbc
antibodi
endpoint
titrat
hemagglutin
assay
antibodyco
srbc
prepar
mix
wv
srbc
suspens
equal
volum
antisrbc
serum
subagglutin
level
incub
mixtur
min
addit
min
assay
porcin
alveolar
macrophag
pam
prepar
polystyren
cm
cell
cultur
petri
dish
corn
inc
corn
ny
usa
concentr
cell
per
ml
media
incub
rpmi
medium
supplement
fc
mm
hepe
sigma
chemic
co
antibioticantimycot
mixtur
h
co
atmospher
cell
gentli
wash
pb
ml
antibodyco
srbc
suspens
ad
control
cell
receiv
amount
uncoat
srbc
mixtur
incub
min
unbound
srbc
remov
rins
pb
cell
fix
stain
diffquick
stain
difco
laboratori
detroit
mi
usa
direct
manufactur
observ
magnif
total
cell
randomli
select
microscop
field
count
proport
rosett
form
cell
calcul
rosett
defin
macrophag
least
three
srbc
associ
membran
assay
independ
repeat
three
time
mean
valu
treat
control
group
calcul
analyz
student
ttest
antibodydepend
enhanc
prrsv
infect
assess
measur
increas
progeni
viru
yield
previous
describ
yoon
et
al
yoon
et
al
briefli
prrsv
isup
mab
b
dilut
tcid
ml
fcsfree
rpmi
medium
test
group
viru
suspens
mix
equal
volum
prestandard
serial
dilut
mab
dilut
test
control
group
prepar
mix
virus
equal
volum
prrsvade
posit
serum
collect
experiment
infect
pig
antibodi
manner
describ
virusmab
mixtur
incub
h
ml
aliquot
mixtur
inocul
triplic
onto
pam
prepar
ratio
pamwel
h
earlier
result
multipl
infect
moi
incub
h
inoculum
replac
rpmi
medium
fc
follow
incub
period
day
end
incub
period
cell
subject
cycl
freezethaw
minu
respect
disrupt
cell
may
still
contain
viru
amount
prrsv
cell
lysat
quantit
viru
titrat
describ
sampl
contain
prrsv
serial
dilut
ml
dilut
sampl
inocul
triplic
onto
confluent
monolay
prepar
h
earlier
plate
incub
day
humid
co
incub
cell
fix
aceton
aqueou
solut
presenc
prrsv
determin
stain
fix
cell
cocktail
prrsvspecif
mab
rural
technolog
inc
brook
sd
usa
viru
titer
sampl
determin
count
fluoresc
foci
well
show
foci
express
fluoresc
foci
unit
ffu
per
millilit
neutral
activ
individu
mab
assess
use
fluoresc
foci
reduct
assay
prrsv
strain
briefli
viru
suspens
contain
approxim
ffuml
base
predetermin
titer
mix
equal
volum
standard
mab
viru
control
prepar
ident
manner
except
mix
prrsvvn
posit
serum
experiment
infect
pig
fcsfree
minim
essenti
medium
mem
sigma
chemic
co
instead
mab
virusmab
virusserum
virusmedium
mixtur
incub
h
ml
mixtur
ad
triplic
well
contain
hold
confluent
cell
monolay
incub
h
inoculum
replac
fresh
mem
medium
supplement
fc
antibioticantimycot
mixtur
cell
incub
day
humid
co
incub
end
incub
period
monolay
fix
aceton
aqueou
solut
stain
antiprrsv
mab
cocktail
viru
titer
sampl
treat
individu
mab
express
ffuml
describ
compar
viru
control
result
neutral
assay
analyz
calcul
percent
reduct
progeni
viru
yield
ffu
presenc
mab
compar
absenc
mab
reduct
yield
observ
mab
consid
possess
neutral
activ
cutoff
reduct
set
base
procedur
use
previou
studi
investig
corapi
et
al
yang
et
al
yoon
et
al
progeni
viru
yield
ade
assay
determin
calcul
ffuml
dilut
mab
assay
well
viru
control
due
work
volum
progeni
viru
yield
ffuml
assess
set
two
three
mabtreat
viru
group
one
untreat
viru
control
time
given
dilut
geometr
mean
progeni
viru
yield
mabtreat
untreat
group
statist
compar
use
wilcoxonkruskalw
rank
sum
test
pairwis
comparison
perform
use
dunnett
method
student
ttest
use
bonferroni
correct
guard
type
error
inflat
dilut
data
treat
untreat
group
statist
compar
gener
regress
model
petri
watson
signific
slope
intercept
determin
p
rosett
assay
approxim
pam
count
form
rosett
incub
srbc
coat
murin
antisrbc
antibodi
less
pam
form
rosett
srbc
pretreat
normal
mous
serum
demonstr
fc
receptor
pam
react
fc
portion
murin
immunoglobulin
fig
mab
character
protein
concerntr
antibodi
titer
elisa
ifa
need
standard
among
mab
use
ifa
antibodi
titer
individu
mab
rang
tabl
elisa
mab
specif
n
protein
ie
hd
show
detect
antigenspecif
respons
howev
linear
relationship
could
obtain
optic
densiti
dilut
data
shown
believ
sigmoid
respons
elisa
could
avoid
od
valu
convert
sp
ratio
elisa
kit
intend
swine
sera
addit
nonlinear
plot
readout
antigenspecif
reactiv
could
demonstr
commerci
elisa
mab
particularli
specif
protein
may
attribut
lack
particular
mab
epitop
elisa
kit
differ
antigen
format
ie
linear
versu
conform
thu
mab
standard
mab
would
titer
similar
mab
lowest
titer
accord
ifa
test
result
ie
ifa
titer
neutral
activ
mab
prrsv
isol
summar
fig
monoclon
antibodi
specif
n
protein
hd
neutral
infect
cell
prrsv
use
reduct
progeni
viru
product
cutoff
mab
determin
neutral
activ
replic
inhibit
virus
treat
remain
mab
vitro
ade
assay
use
serial
dilut
mab
reveal
mab
test
lowest
dilut
approxim
ifa
unit
could
categor
group
enhanc
suppress
neither
fig
base
progeni
viru
yield
signific
enhanc
prrsv
infect
p
observ
suggest
epitop
repres
antibodi
associ
ade
prrsv
infect
mean
viru
yield
pam
infect
prrsv
presenc
mab
log
higher
pam
expos
viru
hand
infect
andor
replic
prrsv
pam
significantli
suppress
p
treatment
mab
mean
progeni
viru
yield
reduc
log
log
rel
respect
untreat
control
group
neither
signific
enhanc
suppress
progeni
viru
product
pam
observ
prrsv
pretreat
remain
mab
signific
enhanc
activ
p
mab
prrsv
replic
continu
present
seri
dilut
ie
lower
antibodi
concentr
fig
addit
progeni
viru
yield
pam
appear
increas
prrsv
isup
pretreat
mab
p
higher
dilut
fig
mab
significantli
suppress
progeni
viru
product
pam
lowest
dilut
ie
retain
effect
prrsv
replic
even
concentr
dilut
fig
although
show
similar
effect
fig
statist
mab
along
mab
specif
epitop
protein
consid
suppress
mab
seri
dilut
addit
mab
mab
determin
significantli
suppress
product
prrsv
progeni
viru
pam
seri
dilut
p
fig
comparison
mab
show
signific
suppress
activ
dilut
except
lowest
fig
present
studi
attempt
identifi
antigen
epitop
associ
ade
prrsv
respons
viru
neutral
use
panel
wellcharacter
mab
epitop
variou
prrsv
protein
monoclon
antibodi
commonli
use
purpos
sinc
mab
recogn
distinct
epitop
furthermor
use
mab
purpos
proven
investig
corapi
et
al
halstead
et
al
hohdatsu
et
al
moren
et
al
prohaszka
et
al
gener
ade
infect
envelop
virus
believ
mediat
epitop
associ
envelop
protein
membraneassoci
protein
canceltirado
yoon
observa
fig
product
infecti
progeni
prrsv
porcin
alveolar
macrophag
cell
infect
isup
treat
monoclon
antibodi
specif
distinct
epitop
prrsv
nucleocapsid
protein
valu
repres
mean
differ
progeni
viru
yield
treat
untreat
group
dilut
error
bar
standard
deviat
mean
tion
prrsv
mab
agreement
investig
observ
epitop
associ
ade
determin
resid
kd
nucleocapsid
kd
envelop
protein
wherea
epitop
kd
matrix
kd
protein
mainli
associ
viru
neutral
base
panel
mab
use
studi
worthwhil
note
mab
suppress
prrsv
replic
cell
line
pam
involv
protein
induc
neutral
enhanc
antibodi
demonstr
laboratori
other
gonin
et
al
kwang
et
al
weiland
et
al
yoon
yang
et
al
yoon
et
al
howev
unexpect
antigen
determin
protein
recogn
mab
would
associ
inhibit
prrsv
replic
statist
mab
show
much
stronger
inhibit
prrsv
replic
porcin
alveolar
macrophag
prrsv
natur
target
cell
mab
recogn
epitop
protein
p
north
american
prrsv
isol
protein
report
nonstructur
protein
contrast
describ
structur
protein
european
prrsv
isol
meulenberg
petersenden
besten
recent
studi
report
product
spanish
prrsv
strain
recombin
baculovirus
provid
pig
protect
immun
prrsv
challeng
plana
duran
et
al
investig
remain
determin
role
prrsv
pathogenesi
immun
prrsv
infect
also
enhanc
suppress
treat
mab
specif
epitop
nucleocapsid
n
protein
ie
enhanc
b
suppress
unexpect
observ
sinc
part
n
protein
demonstr
expos
outsid
intact
virion
theoret
observ
possibl
nake
partial
strip
virus
contain
intact
infecti
rna
viru
prepar
use
assay
like
sinc
viru
materi
use
studi
purifi
zonal
centrifug
howev
also
demonstr
requir
intact
infecti
virion
infect
permiss
cell
bypass
ade
pathway
viru
entri
mason
et
al
consequ
observ
may
signific
implic
pathogenesi
prrsv
kd
n
protein
known
highli
immunogen
abund
express
orf
gene
encod
n
protein
earli
stage
infect
demonstr
vitro
vivo
bautista
et
al
loemba
et
al
mardassi
et
al
yoon
et
al
likewis
also
report
high
level
nonneutr
antibodi
specif
n
protein
produc
pig
follow
exposur
nelson
et
al
yoon
et
al
subsequ
prrsv
could
take
advantag
ade
entri
target
cell
ie
macrophag
macrophagelineag
cell
nevertheless
demonstr
result
anti
n
antibodi
may
suppress
effect
state
could
relat
presenc
nake
viru
virion
partial
strip
envelop
viru
suspens
use
assay
vitro
assess
ade
activ
antibodi
affect
variou
factor
includ
isotyp
subtyp
immunoglobulin
hohdatsu
et
al
assay
condit
viru
strain
eg
homolog
versu
heterolog
antibodi
titer
multipl
infect
paramet
measur
enhanc
moren
et
al
b
ochiai
et
al
robinson
et
al
szabo
et
al
factor
taken
consider
studi
includ
isotyp
determin
mab
use
subtyp
thu
result
ade
neutral
assay
describ
present
studi
independ
immunoglobulin
isotyp
subtyp
properti
intrins
epitop
bound
although
isotyp
murin
igg
shown
capabl
enhanc
viru
infect
macrophag
murin
origin
moren
et
al
observ
ade
prrsv
infect
pam
mab
subtyp
distinct
result
previou
studi
ade
fipv
infect
macrophag
felin
origin
mab
corapi
et
al
evalu
abil
mab
specif
envelop
protein
fipv
induc
ade
infect
felin
periton
macrophag
corapi
et
al
mab
capabl
neutral
abil
viru
infect
permiss
cell
line
fifteen
mab
induc
ade
infect
macrophag
one
subclass
remain
four
mab
induc
ade
infect
differ
isotyp
neutral
mab
induc
ade
induc
ade
suggest
might
restrict
subclass
capabl
mediat
ade
viru
infect
also
possibl
differ
abil
fipvspecif
murin
igg
isotyp
mediat
ade
infect
due
differ
bind
affin
murin
isotyp
fcr
felin
macrophag
hohdatsu
et
al
remain
studi
whether
similar
isotyp
restrict
exist
murin
mab
capabl
enhanc
suppress
prrsv
infect
pam
note
specif
classif
prrsv
mab
role
vn
ade
may
conclus
mab
sinc
antibodi
concentr
individu
mab
adjust
similar
antibodi
level
qualiti
control
vitro
assay
previou
studi
suggest
prrsv
infect
inhibit
enhanc
presenc
antibodi
depend
upon
ratio
immunoglobulin
avail
specif
epitop
antibodi
molecul
virion
number
hawk
lafferti
porterfield
yoon
et
al
yoon
et
al
observ
also
made
studi
polyclon
antiprrsv
swine
serum
may
attribut
fact
antiserum
consist
variou
subpopul
antibodi
repres
differ
specif
affin
avid
sinc
mab
recogn
singl
epitop
phenomenon
expect
occur
anticip
role
individu
mab
ade
vn
distinct
shown
gener
regress
model
except
mab
suppress
prrsv
replic
viru
treat
higher
concentr
p
antibodi
concentr
lower
serial
dilut
suppress
effect
mab
disappear
becam
enhanc
howev
trend
consid
statist
signific
p
antibodydepend
enhanc
viru
infect
signific
obstacl
develop
effect
vaccin
control
certain
viral
diseas
public
health
veterinari
import
ade
prrsv
infect
suspect
one
possibl
reason
rel
ineffect
vaccin
control
prr
present
studi
provid
antigen
basi
develop
subunit
vaccin
would
induc
protect
immun
minim
risk
ade
howev
molecular
character
epitop
postul
induc
enhanc
neutral
antibodi
studi
remain
explor
biolog
signific
find
pig
also
remain
determin
work
use
murin
monoclon
antibodi
repres
model
solv
problem
ade
practic
applic
find
remain
seen
anim
studi
furthermor
presenc
absenc
epitop
associ
ade
andor
vn
assess
use
expand
mab
